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HIV coinfection accelerates disease progression in chronic hepatitis C and reduces sustained antiviral responses (SVR) to inter-
feron-based therapy. New direct-acting antivirals (DAAs) promise higher SVR rates, but the selection of preexisting resistance-
associated variants (RAVs) may lead to virologic breakthrough or relapse. Thus, pretreatment frequencies of RAVs are likely
determinants of treatment outcome but typically are below levels at which the viral sequence can be accurately resolved. More-
over, it is not known how HIV coinfection influences RAV frequency. We adopted an accurate high-throughput sequencing
strategy to compare nucleotide diversity in HCV NS3 protease-coding sequences in 20 monoinfected and 20 coinfected subjects
with well-controlled HIV infection. Differences in mean pairwise nucleotide diversity (), Tajima’s D statistic, and Shannon
entropy index suggested that the genetic diversity of HCV is reduced in coinfection. Among coinfected subjects, diversity corre-
lated positively with increases in CD4 T cells on antiretroviral therapy, suggesting T cell responses are important determinants
of diversity. At a median sequencing depth of 0.084%, preexisting RAVs were readily identified. Q80K, which negatively impacts
clinical responses to simeprevir, was encoded by more than 99% of viral RNAs in 17 of the 40 subjects. RAVs other than Q80K
were identified in 39 of 40 subjects, mostly at frequencies near 0.1%. RAV frequency did not differ significantly between monoin-
fected and coinfected subjects. We conclude that HCV genetic diversity is reduced in patients with well-controlled HIV infection,
likely reflecting impaired T cell immunity. However, RAV frequency is not increased and should not adversely influence the out-
come of DAA therapy.
Coinfection with hepatitis C virus (HCV) is an important causeof morbidity and mortality among persons infected with HIV
(1, 2). Disease progression is accelerated, and coinfected patients
respond poorly to treatment with pegylated alpha interferon and
ribavirin (Peg-IFN/RBV) compared to those infected only with
HCV (monoinfection). The rate of sustained antiviral response
(SVR) with Peg-IFN/RBV was only 19 to 22% in a large, interna-
tional multicenter study of coinfected patients (3), less than half
that observed in monoinfected patients. The addition of direct-
acting antiviral (DAA) therapies to Peg-IFN/RBV significantly en-
hances SVR rates in monoinfected patients (4, 5). Four DAAs have
been approved thus far for use in the United States, three of which
(boceprevir, telaprevir, and simeprevir) target the viral NS3/4A
protease (6 and http://www.hcvguidelines.org). Protease inhibi-
tors show promise when used in combination with Peg-IFN for
treatment of persons coinfected with HIV (7–9) and likely will be
key components of all oral, interferon-sparing therapies for hep-
atitis C in the future. Nonetheless, experience with the use of
DAAs in coinfected patients remains limited.
In monoinfected patients, HCV variants resistant to NS3/4A
protease inhibitors emerge rapidly unless the drugs are used in
combination with other inhibitors of HCV replication, such as
Peg-IFN/RBV (10, 11). Even with concomitant Peg-IFN/RBV,
however, virologic breakthrough or relapse occurred in as many as
11 to 14% of coinfected patients treated in phase IIa trials of HCV
protease inhibitors (7, 12). Resistant HCV variants emerging dur-
ing DAA therapy likely represent preexisting minor quasispecies
that become predominant due to the selective pressure of the
drugs (13). In part, this reflects the highly replicative nature of
HCV infection, with large numbers of new virions produced each
day (5  1012) in the typical infected individual (14), coupled
with error-prone genome replication. Thus, the response to DAA
therapy and the risk of emergence of resistant HCV variants may
be influenced by the frequency and fitness of preexisting resis-
tance-associated variants (RAVs) (15, 16). Preexisting RAVs likely
will be particularly important in interferon-sparing treatment reg-
imens consisting solely of combinations of DAAs.
An important question is whether the frequency of RAVs is
increased in HCV treatment-naive, coinfected persons. This
might be expected if the genetic diversity of HCV is enhanced in
coinfection by impaired host responses with attendant reductions
in the clearance of the virus. Indeed, some previous studies suggest
increased diversity within the envelope-coding region of the HCV
genome in coinfected versus monoinfected subjects (17–19).
However, HIV diversity decreases with advancing immunosup-
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pression (20), and other studies suggest that the genetic diversity
of HCV is reduced in coinfected persons (21–23). Still other stud-
ies have simply failed to demonstrate a difference (24, 25). These
conflicting results likely are related to variations in cohort size,
sampling depth, the region of the HCV genome examined, and/or
technical errors related to the sequencing strategy.
Efforts to define the population diversity of RNA viruses by
high-throughput sequencing may be confounded by multiple
sources of error (26, 27). Artifactual increases in sequence diver-
sity may be imparted by the misincorporation of nucleotides dur-
ing reverse transcription of RNA to cDNA or during cDNA am-
plification by PCR. Skewed views of viral population structure also
can result from recombination during multiple rounds of PCR,
nonuniform amplification of sequences, or oversampling of small
numbers of genomes in the starting population. Each of these
types of error may obscure the true frequency of minor variants
within a viral population. However, by incorporating a random
8-nucleotide (nt) tag within the primer used for the initial reverse
transcription of a population of viral RNAs while purposefully
undersampling that population with the number of tagging com-
binations, it is possible to identify PCR amplicons derived from a
single RNA template (28). This allows a consensus sequence to be
determined for a cluster of sequencing reads originating from that
one template and largely overcomes PCR-related errors in defin-
ing viral population diversity by high-throughput sequencing. We
exploited this primer ID strategy to accurately sequence HCV
quasispecies at an unprecedented depth.
Our goals in this study were 3-fold: (i) to adapt this high-
throughput primer ID sequencing strategy to the study of HCV
quasispecies; (ii) to compare the degree of genetic diversity of NS3
sequences in monoinfected, treatment-naive patients to that in
coinfected patients who are HCV treatment naive but on stable
antiretroviral therapy (ART); and (iii) to conduct an unbiased and
accurate assessment of the frequency of protease inhibitor RAVs
in HCV treatment-naive subjects and ascertain whether RAV fre-
quencies are altered by HIV coinfection. Our results show that
HCV diversity is decreased in coinfected subjects but that protease
inhibitor RAVs are present at similar frequencies in these two
groups.
MATERIALS AND METHODS
Patient samples. Archived plasma or serum samples were collected be-
tween 2000 and 2011 from 20 monoinfected and 20 coinfected HCV treat-
ment-naive subjects at University of North Carolina hospitals (Table 1).
All were infected with genotype 1a HCV, with serum/plasma HCV RNA
levels of 1 105 IU/ml. Coinfected subjects were on stable antiretroviral
therapy (ART) with serum/plasma HIV RNA ratios of 50 copies/ml and
a median CD4 T cell count of 430 cells/mm3 (interquartile range [IQR],
284 to 665 cells/mm3). The study was approved by the Institutional Re-
view Board of The University of North Carolina at Chapel Hill. All study
subjects provided written informed consent prior to enrollment.
Viral RNA extraction and cDNA synthesis. Viral RNA was extracted
using the QIAamp viral RNA minikit (Qiagen, Valencia, CA). Approxi-
mately 10,000 RNA copies were used as the template for reverse transcrip-
tion with SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA)
TABLE 1 Demographic characteristics of study cohorts
Characteristic
Value by infection type
P valueaMonoinfected (n  20) Coinfected (n  20)
Age, years (means  SD) (median/IQR) 52.0  9.7 (54.0/49.5–56.0) 50.0  4.7 (51.0/48.0–52.5) 0.08
Gender (no. of males) 14 17 0.45
Race
African-American 6 14 0.004
Caucasian 14 4
Other 0 2
Serum/plasma HCV RNA, 106 copies/ml
(means  SD) (median/IQR)
17.5  21.1 (5.79/2.34–33.7) 22.4  23.8 (11.2/3.06–40.1) 0.44
ALTb (U/liter; means  SD) (median/IQR) 98.3  107 (69.0/57.5–91.5) 58.2  27.8 (54.5/36.5–71.0) 0.08
Bilirubin (mg/dl; means  SD) (median/IQR) 0.7  0.4 (0.6/0.4–0.8) 1.0  0.9c (0.8/0.4–1.1) 0.22
Liver biopsy specimens (no. [%]) 15 (75) 13 (65)
Grade activity (median/IQR)d 2 (1/2) 1 (1/1.5) 0.45
Stage fibrosis (median/IQR) 1.5 (0/2) 2 (1/3) 0.26
Serum/plasma HIV RNA (copies/ml) NAe 50
Serum HBsAgf positive (no.) 0/20 0/20
ART daysg (no.; means  SD) (median/IQR) 3,082  1,744 (3,360/1,482–4,442)
CD4 cells/mm3 (means  SD) (median/IQR) NA 515  308 (430/284–665)
CD4h cells/mm3 (means  SD) (median/IQR) NA 364  216 (305/214–509)
a Wilcoxon rank-sum (WRS) for continuous measures and Fisher’s exact test for gender and African-American versus Caucasian race (excluding other races).
b ALT, alanine aminotransferase.
c Bilirubin data were available for 19 coinfected subjects.
d Liver biopsy activity and fibrosis scored by the Metavir system: activity grade was reported for 12 coinfected biopsies only.
e NA, not available.
f HBsAg, hepatitis B virus surface antigen.
g Duration of antiretroviral therapy (ART).
h CD4, the difference between the historic nadir in the CD4 T cell count and that at the time of sampling.
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and a tagging primer with the consensus sequence 5=-ACCTTGCAAGCA
CGCTCTGGCCTTGAA-NNNNNNNN-CT-(barcode)-GAACACCGG
GGACCTCATGGTTGTCTC-3=, in which an 8-nt degenerate primer ID
tag (NNNNNNNN) was followed by a CT linker and a 3- to 4-nt barcode
for sample identification. The 3= end of the tagging primer (underlined
sequence) was customized to provide an exact reverse complement of the
HCV sequence downstream of codon 173 of NS3 in each subject (nt 3945
to 3971 in H77 virus; GenBank accession number AF011751) as deter-
mined by prior population sequencing. Primer sequences are shown in
Table S1 in the supplemental material. Oligonucleotides were purchased
from Integrated DNA Technologies (IDT, Coralville, IA) and purified by
standard desalting.
Amplification of tagged cDNA. Single-stranded cDNA was column
purified using the PureLink PCR purification kit (Invitrogen, Carlsbad,
CA), washing 3 times with binding buffer HC (high cutoff) to remove the
cDNA primer. Primer removal was verified on a subset of samples by
electropherogram analysis using an Experion HighSense RNA microflu-
idic chip (Bio-Rad Laboratories, Hercules, CA). Purified cDNA was am-
plified by nested PCR using the primer 5=-TAYTGCTYGGRCCRGCYG
A-3= (H77c nt 3370 to 3388) for first-round PCR and patient-matched
primers with the consensus sequence 5=-AGTGGAGGGTGAGGTCCAG
AT-3= (H77c nt 3503 to 3523) for second-round PCR. Downstream prim-
ers for nested PCR targeted the 5= end of the tagging primer: 5=-ACCTT
GCAAGCACGCTCTGGC-3= (first round) and 5=-CAAGCACGCTCTG
GCCTTGAA-3= (second round). Amplification was carried out in HS
buffer premix (PrimerSTAR HS kit; TaKaRa, Japan). For first-round
PCR, purified cDNA was divided between two 50-	l reaction mixes, each
subjected to 20 amplification cycles at 98°C for 10 s followed by 68°C for
45 s. One 	l of the combined first-round reaction products was subjected
to the second round of PCR that involved amplification for 20 cycles at
98°C for 10 s and 68°C for 45 s. Reaction products were gel purified using
a 1.5% agarose gel and the MinElute gel extraction kit (Qiagen) with
incubation of the solubilization buffer at room temperature. PCR ampli-
cons were quantified using the PicoGreen double-stranded DNA assay
(Life Technologies, Grand Island, NY).
454 Junior pyrosequencing and bioinformatic processing of raw se-
quences. Amplicons from groups of 4 patient samples, each with a unique
barcode, were pooled in equal molar ratios. Library adaptors were added
by blunt-end ligation using the Rapid Library preparation kit (Roche Di-
agnostics, Indianapolis, IN). Products were analyzed with a Bioanalyzer
using a high-sensitivity DNA chip (Agilent Technologies, Santa Clara,
CA). The resulting library (2  107 copies) was subjected to emulsion-
based clonal amplification with the Lib L emPCR amplification kit (454
Life Sciences, Branford, CT) and sequenced on the 454 GS Junior plat-
form using Titanium chemistry (454 Life Sciences). Raw sequencing reads
were processed through the native amplicon pipeline using default set-
tings. A custom bioinformatics pipeline was used to filter and parse raw
454 primer ID sequencing reads as previously described (28). In short,
individual full-length reads were evaluated for the barcode and primer ID
tag derived from the tagging primer used for cDNA synthesis. When 3 or
more full-length reads from a single patient sample (identical barcode)
contained identical primer IDs, a consensus sequence was constructed by
majority rule.
Viral population diversity. Diversity measures were computed for
populations of unambiguous consensus sequences derived from 3 or
more individual full-length reads as described above. The use of tagging
primers containing numerically greater numbers of random tag se-
quences (in theory, 65,536) than viral RNA copies (10,000) in the re-
verse transcription reaction ensures that the large majority of consensus
sequences are derived from a single RNA template molecule (28). Three
different measures of genetic diversity were used to compare virus popu-
lations from different subjects: average pairwise nucleotide diversity (
)
(29), Tajima’s statistic (D) (30), and the Shannon index (31, 32). Nucle-
otide diversity was computed for the entire read length using a customized
script according to the formula   
ij
xixjij, in which xi and xj are the
frequency of ith and jth sequences, respectively, and 
ij is the number of
differences between them (29). Tajima’s D and sliding-window analysis of

 (100-nt window with 10-nt step size) were computed by DnaSP
v.5.10.01 (33). The Shannon index was calculated using the VEGAN pack-
age of functions for R (34). Haplotypes (defined as unique combinations
of sequence polymorphisms within a consensus sequence) and RAV oc-
currence at specific codons were enumerated with customized bioinfor-
matics scripts in which consensus sequences in each population first were
sorted by diversity, binned by unique variant, and then tallied to obtain
variant frequencies. The RAVs that we searched for were V36A, V36L, or
V36M; Q41R; F43S or F43I; T54A or T54S; V55A or V55I; Q80K or Q80R;
V107I; R109K; S138T; R155G, R155K, R155M, or R155T; A156S, A156V,
or A156D; D168E, D168N, or D168G; and V170T.
Statistical analysis. Differences in diversity indices from monoin-
fected versus coinfected subjects were tested for statistical significance by
a t test with Welch’s adjustment for unequal variances; an exact Wilcoxon
rank-sum (WRS) test was used as a sensitivity analysis. Multivariable as-
sociations between covariates and each diversity index were analyzed with
linear regression. Correlations between diversity indices and clinical pa-
rameters were determined by Spearman’s rank correlation. RAV fre-
quency was modeled using negative binomial regression with coinfection
status and codon nucleotide as predictor variables. This model was fit
using generalized estimating equations (GEE) with an exchangeable
working correlation structure to account for multiple within-subject
codon nucleotide observations. The outcome variable was the number of
occurrences of a given RAV, and the log-transformed number of consen-
sus sequences was included as the offset term; associations were tested
using a modified F-statistic. A binary sensitivity outcome, a RAV fre-
quency of 0%, was evaluated using a logistic GEE model adjusted for
sequencing depth. Analyses were conducted in two-sided format without
adjustment for multiplicity, using Prism 5 for Mac OS X software (GraphPad
Software, Inc.) or SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Primer ID sequencing of HCV RNA. We characterized sequence
diversity within the segment of the HCV genome encoding the
protease domain of NS3 (codons 36 to 173) isolated from serum
or plasma from 40 HCV treatment-naive subjects, 20 of whom
were infected solely with HCV and 20 of whom were coinfected
with HIV (Table 1). All coinfected subjects were on stable ART
with HIV RNA levels of 50 copies/ml. The use of tagged primers
for cDNA synthesis eliminated several common sources of error
in high-throughput sequencing populations of viral genomes
(28). A random 8-nt sequence (termed primer ID) embedded in
each primer labeled cDNA products derived from individual viral
RNA molecules, allowing these molecules to be tracked through
subsequent PCR amplification and high-throughput sequencing
on the 454 Junior platform. Sequencing reads sharing a common
primer ID were clustered, and a consensus sequence was devel-
oped for each cluster of 3 or more reads. Unambiguous consensus
sequences are likely to represent the authentic sequence of a single
RNA molecule given the ratio of possible primer ID sequences and
starting RNA templates (see Materials and Methods).
We used this primer ID strategy to sequence circulating HCV
RNAs in all 40 study subjects. To illustrate the nature of the data
obtained and how they were processed through the bioinformat-
ics pipeline, we show in detail the representative results obtained
with 2 monoinfected (M1 and M2) and 2 coinfected (C1 and C2)
study subjects (Fig. 1). Between 14,461 and 37,864 sequence reads
from each of these samples passed initial filtering, with the maxi-
mum number of reads sharing the same primer ID, varying from
19 to 77 (Table 2). This allowed the construction of between 1,492
and 2,798 consensus sequences per sample (Fig. 1A to D, left),
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most of which (94.3 to 99.7%) were unambiguous by majority
call. Consistent with substantial diversity among virions circulat-
ing in individual subjects, numerous unique haplotypes (defined
as described in Materials and Methods) were present within each
population (Fig. 1A to D, right). The most frequent haplotype
present comprised only 12.5 to 20.0% of all consensus sequences
in any one subject. The number of unique haplotypes representing
1% of the consensus sequences ranged from 5 to 14. The most
frequent 12 to 20 haplotypes comprised 50% of all sequences in
the coinfected subjects. This compared with 36 to 80 haplotypes in
the two monoinfected subjects, suggesting greater haplotype di-
versity in the absence of HIV coinfection.
To ascertain reproducibility, we carried out replicate, indepen-
dent cDNA syntheses and sequencing runs on these 4 subjects.
The two pyrosequencing runs yielded similar numbers of consen-
sus sequences from each subject (Table 2). Excluding several no-
FIG 1 Results of primer ID sequencing of the NS3 protease region in HCV RNA from 4 representative study subjects. Approximately 10,000 copies of viral RNA
from monoinfected (A and B) or coinfected (C and D) subjects were reverse transcribed into cDNA using patient virus strain-specific primers containing both
a sample-specific barcode and an 8-nt random primer ID, amplified by PCR, pooled, and sequenced. From 1,492 to 2,798 consensus sequences were compiled
from alignments of 3 or more 454 Junior reads sharing identical primer ID tags (left), most of which were nonambiguous. Pie charts on the right show the
frequency distribution of unique haplotypes (with more frequent individual haplotypes represented by a unique color) within each sequenced virus population
(range, 552 to 1,255 per sample).
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table exceptions (all cytosine-rich primer ID tags; see Table S2 in
the supplemental material), the most frequent primer IDs ob-
served were unique to each run. The most prevalent primer IDs in
reads from subject C1 were reproducibly enriched for cytosine
(see Table S2), suggesting either poor randomization of the de-
generate region in the tagging primer during synthesis or more
efficient priming for cDNA synthesis. This was not observed with
subsequent samples using different tagging primers for cDNA
synthesis. Importantly, there was strong reproducibility in the fre-
quency of individual haplotypes resolved in the two independent
runs (Fig. 2). Overall, between 1,411 and 3,577 unambiguous con-
sensus sequences were resolved per sample, resulting in popula-
tion depths between 0.07% and 0.03%. Because the probability of
sampling a low-abundance haplotype approximates the Poisson
distribution, this depth of sampling would be expected to identify
variants with frequencies as low as 0.2% to 0.08%. Collectively,
these data show that primer ID sequencing is capable of accurately
resolving genetic diversity in populations of RNA viruses.
Genetic diversity of HCV in monoinfection versus coinfec-
tion. A similar primer ID analysis of NS3 coding sequence was
carried out with RNA extracted from serum or plasma from each
of the other study subjects, thereby providing data on a total of
40 subjects with genotype 1a HCV infection, 20 of whom were
coinfected with HIV but on stable ART with nondetectable HIV
load (50 copies/ml). These cohorts were of comparable age
(monoinfected median age, 54 years; coinfected median age, 51
years) and predominantly male, but coinfected subjects were
more likely to be of African-American, rather than Caucasian,
race (78% and 30%, respectively; P  0.004) and had somewhat
lower serum alanine aminotransferase (ALT) levels (Table 1). The
results of the replicate sequencing runs described above were
pooled and included in this analysis. Median sampling depth was
0.07% for monoinfected subjects and 0.08% for coinfected sub-
jects (Fig. 3A). Each viral population was rich in allelic diversity,
including numerous low-frequency haplotypes. Average pairwise
nucleotide diversity (
) across the NS3 region sequenced varied
by subject but was higher overall in monoinfected (
  0.0143 
0.0069 [means  standard deviations {SD}]) than coinfected
(0.00954  0.0051) subjects (P  0.02; P  0.03 by WRS) (Fig.
3B). A sliding-window analysis revealed localized regions of min-
TABLE 2 Population sequencing throughput and depth in replicate




Raw reads (no.) 116,211 113,932











Consensus sequences (no. of











FIG 2 Reproducibility of primer ID quantitation of HCV haplotype frequency. Data shown represent the frequency of individual haplotypes in two independent
sequencing runs carried out on samples from 2 monoinfected (M1 and M2) and 2 coinfected (C1 and C2) subjects. Haplotypes present at 0.1% in either run
are included. The yellow inset (expanded in the middle) shows those haplotypes present between 0.1 and 3%, while the blue inset (expanded to the right) shows
those between 0.1 and 1%. The dashed line represents the line of identity. Haplotype frequency was grouped into 4 categories: 0.5%, 0.5 to 1.0%, 1.0 to
3.0%, and 3.0%, and agreement was summarized with a weighted Cohen’s kappa coefficient. There was substantial agreement between the two independent
runs (kappa of 0.84). Most (87%, or 431/495) of the haplotypes included in the analysis were detected at a frequency of 0.5% in both runs. When haplotype
frequencies of 1.0% were collapsed into a single group, only 6 of 495 observations were not in agreement (weighted kappa of 0.92).
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imally increased or decreased mean nucleotide diversity within
the linear sequence of the protease-coding region that were con-
served in both patient cohorts (Fig. 4, top). This position depen-
dence did not correlate with the location of active-site residues in
the protease. In contrast, regions of maximum and minimum nu-
cleotide diversity varied widely between individual subjects, sug-
gesting host-specific differences in regional selective forces such as
might be mediated by HLA-restricted T cell responses (Fig. 4,
middle and lower). Nucleotide diversity was not significantly as-
sociated with sequencing depth, HCV RNA copy number, levels of
ALT or bilirubin, age, or sex in univariate models (P  0.05).
Tajima’s D statistic reflects the deviation between the observed
and expected distribution of allelic frequencies at mutation-drift
equilibrium (30). Strongly negative values of D may reflect recent
FIG 3 NS3 sequence diversity in monoinfected and coinfected patient cohorts of 20 patients each. (A) Sequencing depth (1/n, where n is the number of
nonambiguous consensus sequences constructed from 3 or more 454 Junior sequencing reads containing identical primer IDs). (B) Nucleotide diversity (
). (C)
Tajima’s D statistic. (D) Shannon entropy index. Bars indicate medians  quartiles. Significance (P) was assessed by a two-sided Welch t test.
FIG 4 Sliding-window analysis of pairwise nucleotide diversity (
) across the NS3 protease-coding region (NS3 residues 36 to 175). His57, Asp81, and Ser139
represent the catalytic triad within the active site of the protease. (A) Mean nucleotide diversity within 100-nt windows with a 10-nt step in monoinfected (blue;
n  20), coinfected (red; n  20), and all (black; n  40) subjects. The nucleotide numbering represents the midpoint in each window. Diversity was higher in
monoinfected subjects in all regions of the sequence. (B and C) Nucleotide diversity calculated for virus populations in individual monoinfected and coinfected
subjects (n  20 each). A repeat analysis using 30-nt windows with a 10-nt step generated similar results, with no suggestion of reduced diversity surrounding the
active-site residues (data not shown).
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selective sweeps, population bottlenecks, and population expan-
sion, whereas positive values can indicate balancing selection, mi-
gration, and population subdivision. Tajima’s D was 2.0 in all
but two subjects, indicating an excess of low-frequency polymor-
phisms. While the mean value of Tajima’s D for coinfected sub-
jects (2.45  0.18) was lower than that for monoinfected sub-
jects (2.33  0.23), this difference did not achieve statistical
significance (P  0.08; P  0.15 by WRS) (Fig. 3C). We also
computed the Shannon diversity index for each virus population.
This measure captures both the number of variants and the even-
ness of their distribution (how similar their numbers are) within
the population (31, 32). An increase in the number of unique
haplotypes and/or an increase in the evenness of their distribution
will result in an increased Shannon index. Consistent with other
measures of diversity, the Shannon index showed a trend toward
higher values in virus populations from monoinfected versus
coinfected subjects (mean results of 4.96  1.07 versus 4.34 
1.03; P  0.07; P  0.10 by WRS) (Fig. 3D).
As significantly more coinfected subjects were African-Amer-
ican than monoinfected subjects, we explored the association be-
tween these measures of HCV diversity and race in a series of
multivariable linear regression models. Nucleotide diversity was
numerically greater in monoinfected subjects among both Afri-
can-Americans and whites (Fig. 5). Moreover, in a model adjusted
for sequencing depth and HCV RNA copy number but ignoring
race, coinfection was associated with lower nucleotide diversity
(P  0.02), while in a comparable model ignoring coinfection
status, no association with race was detected (P  0.12). However,
in a model that included coinfection, race, sequencing depth, and
HCV RNA level, neither coinfection (P  0.11) nor race (P 
0.52) was statistically significant, but interpretation of this model
was limited by the colinearity of coinfection and race (see Table S3
in the supplemental material). None of the evaluated covariates
were significantly associated with Tajima’s D in multivariable
models (see Table S4). In univariate analyses, lower Shannon in-
dices were associated with African-American race (P  0.006) and
marginally associated with coinfection status (P  0.07). The as-
sociation between lower Shannon index and African-American
race also was evident in a nonparametric sensitivity analysis (P 
0.01 by WRS), as well as a multivariable model including coinfec-
tion status (P  0.53) and race (P  0.03) (see Table S5). The
biological significance of the association between race and Shan-
non index is uncertain (see Discussion).
CD4 T cell counts and HCV diversity in coinfected subjects.
While substantial overlap between coinfection status and race
made it difficult to ascertain the individual impact of these vari-
ables, these analyses point collectively toward a reduction in the
genetic diversity of the NS3 protease-coding sequence in coin-
fected subjects. Since the selective pressure of T cell responses
acting only on certain variants within the replicating HCV quasi-
species ensemble could generate greater diversity, we sought evi-
dence for a correlation between the CD4 T cell count at the time
of sample collection and NS3 sequence diversity. The coinfected
patients had been receiving ART for a median of 110 months
(range, 8 to 194) when studied. As expected, both the CD4 T cell
count at the time of sampling and the difference between the his-
toric nadir in the CD4 T cell count (Spearman’s r  0.701; P 
0.001) and that at the time of sampling (CD4) (r  0.623 and
P  0.003) correlated strongly with the length of ART therapy
(Fig. 6A). Nucleotide diversity and Tajima’s D trended toward
increases with increasing CD4 count, but these correlations did
not reach statistical significance (r  0.361 and P  0.12 for 
 and
r  0.310 and P  0.18 for Tajima’s D). However, both 
 (r 
0.505; P  0.023) and Tajima’s D (r  0.505 and P  0.023) were
positively correlated with CD4 (Fig. 6C). These diversity mea-
sures also tended to be higher in subjects with longer lengths of
ART, but this relationship was statistically significant only for Ta-
jima’s D (r  0.548; P  0.01) (Fig. 6D). The Shannon index
FIG 5 Exploratory analysis of HCV diversity measures by racial groups and
coinfection status. Boxplots showing medians, interquartile ranges, and means
() for average pairwise nucleotide diversity (
) (A), Tajima’s D (B), and the
Shannon index (C) of NS3 protease domain sequences from monoinfected
and coinfected subjects of Caucasian (n  14 and 4, respectively) and African-
American (n  6 and 14) race. An exact Wilcoxon rank-sum test was used to
determine P values post hoc. This study was not designed to assess differences in
HCV genetic diversity across racial groups.
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showed slight, statistically insignificant downward trends with
both CD4 and length of ART (Fig. 6C and D, right). Taken
together, these analyses suggest that the reduced diversity of NS3
sequence in these subjects with well-controlled HIV coinfection
likely is related to residual impaired cellular immunity (see Dis-
cussion).
Protease inhibitor RAVs. Virologic failure in patients receiv-
ing potent DAA regimens typically is associated with the emer-
gence of RAVs (35). Theoretical considerations suggest that these
emergent variants represent preexisting minor quasispecies that
become dominant under the selective pressure of the drugs (13).
There is good experimental evidence to support this concept, but
only limited information is available concerning the baseline fre-
quencies of such variants in treatment-naive patients (36, 37).
FIG 6 NS3 sequence diversity, CD4 T cell counts, and length of ART in the coinfected patient cohort (n  20). (A) CD4 T cell count (left) and CD4 (the
difference between the historic nadir in the CD4 T cell count and that at the time of sampling, right) increased with increased duration of ART. (B) CD4 cell
count and nucleotide diversity (
), Tajima’s D, and Shannon index of NS3 sequences from coinfected subjects (n  20). (C) CD4 and nucleotide diversity (
),
Tajima’s D, and Shannon index of NS3 sequences from coinfected subjects (n  20). (D) Length of ART and nucleotide diversity (
), Tajima’s D, and Shannon
index of NS3 sequences in coinfected subjects (n  20). Correlations were assessed by Spearman’s rho.
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Since primer ID sequencing provides a uniquely accurate and
unbiased approach to assessing the prevalence of low-frequency
variants, we examined the consensus sequences recovered from
monoinfected and coinfected subjects for the presence of known
protease inhibitor RAVs (see Materials and Methods).
Q80K was the most prevalent RAV identified in both patient
cohorts, both in terms of the proportion of subjects in which it was
identified (Fig. 7A) and its frequency within the virus population
when present (Fig. 7B). Q80K is associated with modest resistance
to newer macrocyclic NS3/4A protease inhibitors, and it nega-
tively impacts the therapeutic response to simeprevir (16, 38, 39).
However, it is a common polymorphism in genotype 1a virus.
Over 99% of the consensus sequences in 11/20 (55%) monoin-
fected and 6/20 (30%) coinfected subjects encoded Q80K. To fo-
cus on low-frequency RAVs, we excluded Q80K (both AAA and
AAG codons) from further analyses, but not Q80R variants that
are associated with similar resistance (38) but were much less
prevalent (0.25% in all subjects). Except for one coinfected in-
dividual (C19, who was sequenced to a depth of only 0.85%), one
or more low-frequency RAVs were detected in all subjects. Impor-
tantly, the overall frequency of RAVs (excepting Q80K) was sim-
ilar in monoinfected versus coinfected subjects, and the median
cumulative frequency was 0.37% versus 0.53% (P  0.31; P  0.28
by WRS) (Fig. 7C) despite one coinfected subject (C2) with over
99% V55I. The distribution and frequency of RAVs involving dif-
ferent codons in individual subjects is shown as a heat map in Fig.
8. A negative binomial GEE model demonstrated that the fre-
quency of RAVs varied significantly at different codons (P 
0.0001, excluding Q80K, V55I-AUA [high frequency], and one
unobserved RAV, V55A-GCU), likely reflecting differences in the
fitness of these variants (40). However, the frequency of RAVs
across the codons was not significantly associated with coinfection
status (P  0.20). Results were similar when an RAV frequency of
0% was evaluated with a logistic GEE model (P  0.004 for
codon position; P  0.64 for coinfection).
Despite the remarkable depth and accuracy of the primer ID
sequencing protocol (Fig. 2), most RAVs existed in these treat-
ment-naïve subjects at frequencies sufficiently low to confound
their unambiguous resolution. If the high-frequency Q80K and
V55I (subject C2) RAVs are excluded, 122 of the 296 RAVs iden-
tified in the 64,338 consensus sequences we constructed from all
40 subjects were single occurrences within the viral population
(termed singlets). While each of these consensus sequences was
built from a minimum of three sequencing reads, such a singlet
FIG 7 NS3/4A inhibitor resistance-associated variants (RAVs; 41 codons) identified by primer ID sequencing in monoinfected and coinfected subjects.
(A) Percentage of monoinfected and coinfected subjects in which individual RAVs were identified. (B) Mean detection frequency of RAVs when present,
shown as the percentage of consensus reads in those subjects with the RAV. Bars indicate standard errors of the means. (C) Mean cumulative sum of all
RAVs except those encoding Q80K (cumulative percentage of consensus reads) in individual study subjects. Bars represent medians and IQR. P  0.28
by Wilcoxon rank-sum test.
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cannot be differentiated unambiguously from an error introduced
during reverse transcription of the viral genome. Nonetheless, two
lines of evidence suggest that many of these singlets represent
actual variants in the viral population and not artifactual diversity.
First, in the 4 sequencing runs that were independently replicated
(Fig. 2), approximately half of the singlet RAVs identified in any
one run were confirmed in one or more consensus sequences in
the paired run. This accords with sampling probabilities predicted
by the binomial distribution and a formal series of Monte Carlo
simulations (not shown). Second, there was substantial associa-
tion between occurrences of singlet and nonsinglet RAVs involv-
ing specific codons (see Fig. S1 in the supplemental material). This
would not be expected were singlets to arise randomly from errors
introduced during reverse transcription.
DISCUSSION
The emergence of resistant HCV variants is a significant concern
for coinfected patients treated with interferon-sparing combina-
tions of DAAs, as it is for those infected only with HCV. These
variants likely exist as a minor fraction of the HCV quasispecies
swarm prior to therapy and become dominant due to the selective
pressure of DAAs on the viral population (13). The frequency of
RAVs in treatment-naive individuals, coupled with their fitness, is
likely to determine both the rapidity with which resistance
emerges as well the probability of successfully eliminating the vi-
rus. Similarly, the extent to which such RAVs persist off treatment
in patients who fail DAA therapy could determine the response to
retreatment with drugs that have similar resistance profiles.
Whether protease inhibitor RAVs are more or less frequent in
patients with HIV coinfection is an important question that we
have addressed here using a novel and extremely accurate high-
throughput sequencing method in which sequence reads gener-
ated from a single viral RNA template are tagged (28). This strat-
egy allows for the development of a consensus sequence for each
RNA template and thereby obviates a variety of technical errors
that may otherwise serve to artifactually enhance the diversity ob-
served within a viral population. It also permits reliable detection
of low-frequency haplotypes.
FIG 8 Heat map showing the presence and relative frequency of individual RAVs across virus populations from the two patient cohorts. Negative binomial
generalized estimating equations demonstrated that RAV frequency varied significantly by codon (P  0.0001, excluding Q80K, V55I-AUA, and one unobserved
RAV, V55A-GCU), but no significant dependence on coinfection status was observed (P  0.20).
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High-throughput pyrosequencing of RNA viruses can be con-
founded by multiple types of errors. Artifactual diversity can be
imparted by base misincorporation during reverse transcription
of viral RNA to cDNA or by DNA recombination during multiple
rounds of PCR, biased PCR amplification of sequence, and over-
sampling of small numbers of genomes (26, 27). Each of these
types of error may obscure the true frequency of minor variants
within a viral population and provide an inaccurate view of the
architecture of viral quasispecies. The primer ID strategy we ad-
opted was designed to avoid many of these pitfalls and was
adapted from a procedure developed to examine HIV diversity
(28). In previous studies of HIV, 80% of the diversity present in
individual sequencing reads from the Roche 454 platform was
eliminated by clustering and developing a consensus sequence
from 3 or more reads sharing a common primer ID tag (28). The
single most important modification required to achieve reliable
amplification of HCV sequence with random primer ID incorpo-
ration into cDNA was the use of tagging primers customized to
provide an exact match with the patient’s virus based on the re-
sults of prior population sequencing. This was mandated by the
diversity of sequence 3= to the NS3 coding region of interest in
different genotype 1a viruses that precluded development of a
universal primer.
Nonetheless, the primer ID approach cannot eliminate artifac-
tual diversity resulting from errors in reverse transcription of RNA
to cDNA, which may occur as often as 1 in 5,000 bases (0.02%)
(28). We approached this limit in our analysis of some samples.
The depth was 0.015% and 0.02% in subjects C2 and M1, respec-
tively, achieved by pooling results from two independent runs.
However, the median depth to which we sequenced was 0.08%
overall, and the typical frequency of the RAVs we detected was
substantially greater than 0.02% (Fig. 7B). While the identifica-
tion of a RAV in a single consensus sequence from one sample
does not unambiguously demonstrate the presence of that RAV in
the original viral population, the single occurrences we observed
likely represent true viral diversity for reasons discussed above.
They do not appear randomly distributed across codons (see Fig.
S1 in the supplemental material), as might be expected from base
misincorporation during reverse transcription of viral RNAs. An
alternative to the primer ID strategy that allows for highly accurate
high-throughput sequencing independent of errors in reverse
transcription is CirSeq, in which tandem repeats of viral sequence
generated from circularized fragments of the genome are se-
quenced (41). This approach, while offering greater accurate
depth of reads than the primer ID method, is limited to sequenc-
ing very small genome fragments; therefore, it provides less insight
into linkage.
In this study, we focused exclusively on HCV sequence encod-
ing the protease domain of NS3 protein. However, we anticipate
that the primer ID approach will work equally well and reveal
comparable degrees of genetic diversity and RAV frequencies in
regions of the HCV genome that encode alternative DAA targets,
such as the NS5A protein or the NS5B RNA-dependent RNA poly-
merase. Ongoing primer ID studies of the 5= NS5A coding se-
quence provide preliminary evidence for this, and in four
monoinfected subjects we have generated sequence reads with di-
versity comparable to what we observed in the NS3 region (com-
parable values for 
 and Tajima’s D) (F. Hu, S. Zhou, and S. M.
Lemon, unpublished data).
HIV coinfection profoundly influences the course of HCV in-
fection in ways that remain incompletely understood (1, 2). Thus,
one of the most interesting findings to emerge from this study was
the lower diversity of HCV NS3 sequence in coinfected compared
to monoinfected subjects (Fig. 3B to D). Relatively few previous
studies have compared the population structure of HCV in coin-
fected and monoinfected subjects, and none have approached the
depth and accuracy of the analysis or number of subjects in this
study. Most previous studies have focused on hypervariable re-
gion 1 (HVR1) within the E2 envelope protein, which is known to
be targeted by antibodies to the virus (42), and not HCV non-
structural proteins targeted by DAAs. Using a variety of methods,
and not always achieving statistical significance, several previous
studies suggested trends toward greater population diversity in
coinfected versus monoinfected persons (17–19). On the other
hand, other studies have suggested that HCV quasispecies diver-
sity is reduced in coinfected subjects (21, 23, 43, 44), and that
diversity within HVR1 is increased by successful ART (23, 45–48).
Only one previous study examined the impact of HIV coinfection
on NS3 sequence diversity. This involved a comparison of 3
monoinfected and 6 coinfected individuals by clonal sequencing
and revealed no significant differences (21). Our study differs
from these previous studies in several important respects, includ-
ing both the greater accuracy provided by the primer ID method
and much larger patient cohorts (20 subjects in each group).
The coinfected patients we studied had been receiving ART,
most for many years, and all had an undetectable HIV load (50
copies/ml). Nonetheless, average pairwise nucleotide diversity (
)
was significantly lower in the coinfected than the monoinfected
subjects (Fig. 3B). Trends toward reduced population diversity
also were evident in Tajima’s D statistic and in the Shannon en-
tropy index (Fig. 3C and D). Nucleotide diversity and Tajima’s D
were significantly associated with the difference between CD4 T
cell count at the historic nadir prior to initiation of ART and that
at the time of sample collection (Fig. 6C). These associations were
not large but are consistent with the hypothesis that reduced im-
munological pressure on the virus limits the selection of escape
mutants and reduces diversity (43, 44). ART enhances this pres-
sure and results in an increase in diversity. It is notable that these
effects on HCV population structure were observed with a median
CD4 T cell count of 430 cells/mm3 (IQR, 284 to 665 cells/mm3).
Similar increases in sequence diversity within the hypervariable
region of the E2 protein-coding region of HCV have been linked
to immune reconstitution and increasing CD4 T cell counts fol-
lowing institution of ART in coinfected patients (45). This inter-
pretation is consistent with a large body of evidence indicating
that CD4 and CD8 T cell responses shape HCV quasispecies
evolution through selection of escape variants, particularly in the
early weeks of HCV infection (49–52).
A significantly greater proportion of the coinfected subjects we
studied were African-American, whereas the monoinfected sub-
jects predominantly were Caucasian (Table 1). While the study
was not designed to assess the influence of race on HCV genetic
diversity, post hoc analyses suggested an association between lower
Shannon entropy indices and African-American race that was ev-
ident in both univariate and multivariable analyses. In contrast,
lower Shannon indices were only marginally associated with coin-
fection status in the univariate analysis (P  0.07). This suggests
that African-American subjects have fewer unique haplotypes
and/or a less even distribution of these haplotypes among circu-
lating HCV quasispecies. Why this should be so for African-Amer-
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icans is not clear, but it is intriguing to consider that it reflects a
greater prevalence of interleukin-28B (IL-28B) (interferon
lambda 3 [IFN-3]) genetic polymorphisms unfavorable for im-
mune control of HCV (53, 54). Unfortunately, data concerning
IL-28B genotypes were not available for most of the subjects we
studied. Other genetic polymorphisms also have been associated
with reduced control of HCV infection, including polymorphisms
in IFN-, human leukocyte antigen (HLA), or natural killer (NK)
cell inhibitory receptor genes (55, 56).
Is the difference in the genetic diversity of HCV that we docu-
mented between monoinfected and coinfected subjects of clinical
significance? Of the 41 specific protease inhibitor RAVs we
searched for, one or more were present in all but 1 of the 40
patients we studied (Fig. 7). These data provide direct experimen-
tal evidence supporting the premise that such RAVs naturally exist
in treatment-naive HCV quasispecies (13). Antiviral resistance
likely results from the selection of these preexisting variants under
drug pressure. Importantly, although one coinfected subject (C2)
had a high proportion of V55I (99.9%) and another patient
(C3) had R155G (1.76%) and A156S (1.08%) variants, the overall
frequency of RAVs was similar in coinfected and monoinfected
subjects (Fig. 7C). Moreover, we observed a near-zero correlation
between the frequency of RAVs and CD4 cell count (not shown).
We conclude that while pairwise nucleotide diversity is signifi-
cantly reduced within the NS3 coding region of HCV in coinfected
patients with well-controlled HIV infection, the frequency of pre-
existing RAVs is similar to that in monoinfected patients and will
not by itself influence the outcome of NS3/4A protease inhibitor
therapy. The extent to which the response to DAA therapy will be
reduced by the subtle impairment of T cell responses to HCV that
our data suggest exists in coinfected patients with well-controlled
HIV infection remains to be determined.
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